Population: Adults (18-64 years)

Wiedemann

France
|
2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • Monkeypox virus
  • Vaccination
  • MVA-BN

León-Herrera

Spain
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome
  • Non pharmacological intervention
  • Rehabilitation

Mico-Cerda

Spain
|
2013-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus

SIREN Winter Pressures sub-study

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Healthcare workers
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

Santus

Italy
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

Havlin

Czech Republic
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Vaccination
  • Arexvy

Redjoul

France
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Vaccination

ARF-RSV

France
|
2023-2026
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • Respiratory syncytial virus
  • Blood sample

SPIRAV

France
|
2025-2025
  • Adults (18-64 years)
  • Pregnant women
  • Hospital
  • Outpatient clinic
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Vaccination
  • Nirsevimab
  • Abrysvo

BUCOSS RSV 60+

Germany
|
2022-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

RESP-VIR

Italy
|
2025-2026
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Infants (<1 year)
  • Children (1-11 years)
  • Adolescents (12-17 years)
  • Hospital
  • Non-hospital health centre
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Adenovirus
  • Rhinovirus
  • Parainfluenza Virus
  • Metapneumovirus

RAPID

The Netherlands
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • Respiratory syncytial virus